S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-08-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000967944.12345.32 |
| _version_ | 1797281698313928704 |
|---|---|
| author | Olivier Demaria Guillaume Habif Francois Le Floch Marianna Muller Laura Chiossone Romain Remark Marie Vetizou Nadia Maurel Ariane Morel Laurent Gauthier Yannis Morel Carine Paturel Eric Vivier |
| author_facet | Olivier Demaria Guillaume Habif Francois Le Floch Marianna Muller Laura Chiossone Romain Remark Marie Vetizou Nadia Maurel Ariane Morel Laurent Gauthier Yannis Morel Carine Paturel Eric Vivier |
| author_sort | Olivier Demaria |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:01:11Z |
| format | Article |
| id | doaj.art-a765401104414a5aab8222c50543e9c1 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:01:11Z |
| publishDate | 2023-08-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a765401104414a5aab8222c50543e9c12024-03-03T03:24:50ZengWileyHemaSphere2572-92412023-08-017e123453210.1097/01.HS9.0000967944.12345.32202308003-00160S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMASOlivier Demaria0Guillaume Habif1Francois Le Floch2Marianna Muller3Laura Chiossone4Romain Remark5Marie Vetizou6Nadia Maurel7Ariane Morel8Laurent Gauthier9Yannis Morel10Carine Paturel11Eric Vivier121 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, France1 Innate Pharma, Marseille, Francehttp://journals.lww.com/10.1097/01.HS9.0000967944.12345.32 |
| spellingShingle | Olivier Demaria Guillaume Habif Francois Le Floch Marianna Muller Laura Chiossone Romain Remark Marie Vetizou Nadia Maurel Ariane Morel Laurent Gauthier Yannis Morel Carine Paturel Eric Vivier S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS HemaSphere |
| title | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_full | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_fullStr | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_full_unstemmed | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_short | S258: IPH6501 IS A FIRST-IN-CLASS TETRASPECIFIC ANTIBODY-BASED NATURAL KILLER CELL ENGAGER THERAPEUTIC DEVELOPED FOR THE TREATMENT OF B-CELL NON-HODGKIN’S LYMPHOMAS |
| title_sort | s258 iph6501 is a first in class tetraspecific antibody based natural killer cell engager therapeutic developed for the treatment of b cell non hodgkin s lymphomas |
| url | http://journals.lww.com/10.1097/01.HS9.0000967944.12345.32 |
| work_keys_str_mv | AT olivierdemaria s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT guillaumehabif s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT francoislefloch s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT mariannamuller s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT laurachiossone s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT romainremark s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT marievetizou s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT nadiamaurel s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT arianemorel s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT laurentgauthier s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT yannismorel s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT carinepaturel s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas AT ericvivier s258iph6501isafirstinclasstetraspecificantibodybasednaturalkillercellengagertherapeuticdevelopedforthetreatmentofbcellnonhodgkinslymphomas |